Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels
- PMID: 16732431
- PMCID: PMC11136405
- DOI: 10.1007/s00018-006-6037-3
Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels
Abstract
We investigated the involvement of endocannabinoids in the control of neuronal damage and memory retention loss in rodents treated with the beta-amyloid peptide (1-42) (BAP). Twelve days after stereotaxic injection of BAP into the rat cortex, and concomitant with the appearance in the hippocampus of markers of neuronal damage, 2-arachidonoyl glycerol, but not anandamide, levels were enhanced in the hippocampus. VDM-11 (5 mg/kg, i.p.), an inhibitor of endocannabinoid cellular reuptake, significantly enhanced rat hippocampal and mouse brain endocannabinoid levels when administered sub-chronically starting either 3 or 7 days after BAP injection and until the 12-14th day. VDM-11 concomitantly reversed hippocampal damage in rats, and loss of memory retention in the passive avoidance test in mice, but only when administered from the 3rd day after BAP injection. We suggest that early, as opposed to late, pharmacological enhancement of brain endocannabinoid levels might protect against beta-amyloid neurotoxicity and its consequences.
Similar articles
-
Molecular reorganization of endocannabinoid signalling in Alzheimer's disease.Brain. 2011 Apr;134(Pt 4):1041-60. doi: 10.1093/brain/awr046. Brain. 2011. PMID: 21459826 Free PMC article.
-
The endocannabinoid, anandamide, augments Notch-1 signaling in cultured cortical neurons exposed to amyloid-β and in the cortex of aged rats.J Biol Chem. 2012 Oct 5;287(41):34709-21. doi: 10.1074/jbc.M112.350678. Epub 2012 Aug 13. J Biol Chem. 2012. PMID: 22891244 Free PMC article.
-
Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404.Eur J Neurosci. 2004 Jun;19(11):2991-6. doi: 10.1111/j.0953-816X.2004.03433.x. Eur J Neurosci. 2004. PMID: 15182306
-
Endocannabinoid metabolic pathways and enzymes.Curr Drug _targets CNS Neurol Disord. 2005 Dec;4(6):615-23. doi: 10.2174/156800705774933104. Curr Drug _targets CNS Neurol Disord. 2005. PMID: 16375679 Review.
-
_targeted lipidomics as a tool to investigate endocannabinoid function.Int Rev Neurobiol. 2009;85:35-55. doi: 10.1016/S0074-7742(09)85004-6. Int Rev Neurobiol. 2009. PMID: 19607960 Review.
Cited by
-
Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells.Glia. 2023 Jan;71(1):103-126. doi: 10.1002/glia.24172. Epub 2022 Mar 30. Glia. 2023. PMID: 35353392 Free PMC article. Review.
-
Endocannabinoid Receptors in the CNS: Potential Drug _targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.Curr Neuropharmacol. 2020;18(8):769-787. doi: 10.2174/1570159X18666200217140255. Curr Neuropharmacol. 2020. PMID: 32065105 Free PMC article. Review.
-
Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer's disease.J Neuroinflammation. 2018 May 24;15(1):158. doi: 10.1186/s12974-018-1174-9. J Neuroinflammation. 2018. PMID: 29793509 Free PMC article.
-
Role of the endogenous cannabinoid system in nicotine addiction: novel insights.Front Psychiatry. 2015 Mar 25;6:41. doi: 10.3389/fpsyt.2015.00041. eCollection 2015. Front Psychiatry. 2015. PMID: 25859226 Free PMC article. Review.
-
Intracellular Molecular _targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions.Antioxidants (Basel). 2022 Oct 18;11(10):2049. doi: 10.3390/antiox11102049. Antioxidants (Basel). 2022. PMID: 36290771 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
